Visiongain Publishes Mycoplasma Testing Market Report 2020-2030

24 July 2020

Visiongain has launched a new report Mycoplasma Testing Market Report 2020-2030: Forecasts by Products (Instruments, Kits & Reagents (PCR Assays, Nucleic Acid Detection Kits, Stains, Elimination Kits, Standards & Controls, and Others) and Services), by Technique (PCR, ELISA, Direct Assays, Indirect Assays, DNA Staining, Microbial Culture Techniques, and Enzymatic Methods), by Application (Cell Line Testing, Virus Testing, End-of Production Cell Testing, and Others), by End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Cell Banks, and Others) and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies in the Market.

Mycoplasmas are the smallest self-replicating organisms which has minimal genome that cannot perform metabolic functions such as production of a cell wall, or synthesis of nucleotides or amino acids. Therefore, they exist strictly as parasites, using diverse organisms as hosts, including humans, animals, insects and plants. Mycoplasma is responsible for causing respiratory tract infection. Mycoplasma can be tested using polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic reaction, or DNA staining. Mycoplasma testing is extensively carried out in pharmaceutical manufacturing industries at several phases of product development to examine its contamination in raw materials and final drug products. It is also performed to identify the presence of Mycoplasma in cell banks and biotechnology laboratories, if not, it can further spoil the cell culture-based research work.

Due to less number of culture methods, researchers are highly focused and involved in the identification and development of more rapid and accurate mycoplasma tests in recent years. The prime advantage of such rapid tests is the high sensitivity, capability of identifying a wide range of mycoplasma species, and cycle time reduction, which further reduces the production time. These rapid methods would also expedite the decision making to minimize the spread of contamination. Leading examples of alternative method for culture-based testing are Nucleic Acid-based Technology (NAT) and Polymerase Chain Reaction (PCR) based service that helps detect contaminants in mycoplasma cell cultures driving the market growth.

The pharmaceutical and biotechnology market across several geographies is growing at a significant rate. According to the International Trade Administration, the global pharmaceuticals market is projected to grow to $1.3 trillion by 2020. As stated by the India Brand Equity Foundation (IBEF), the Indian pharmaceuticals market is expected to reach $55 billion by 2020. Strong growth in the pharmaceutical and biopharmaceutical industries is anticipated to drive the mycoplasma testing market.

The Visiongain report analyst commented “that the pharmaceutical and biotechnology companies are the leading end users where mycoplasma testing is carried out in the research and production of all biopharmaceutical products. Growth in the pharmaceutical and biotechnology sector across the globe serves as a direct driver for supplementary markets such as mycoplasma testing.”

However, for optimal efficacy, mycoplasma testing needs to be conducted by skilled professionals and also needs a certain level of expertise in handling the instruments used in mycoplasma testing. Consequently, the dearth of a sufficiently skilled workforce poses a key challenge to the growth of the mycoplasma testing market.

The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include Bionique Testing Laboratories, Inc., Lonza Group Ltd., Merck KGaA; PromoCell GmbH, ATCC (American Type Culture Collection), Biological Industries Israel Beit Haemek Ltd., Charles River Laboratories International, Inc., Thermo Fisher Scientific, and InvivoGen.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020


Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020


Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020


Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020